Portada›Martes 30 de diciembre de 2025

Biomédicas del NASDAQ ante la SEC, martes 30 de diciembre de 2025

Los 36 documentos que 24 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.

← lunes 29 de diciembre de 2025 · miércoles 31 de diciembre de 2025 →

Va en color lo que cambia el capital o avisa de un riesgo: las emisiones con precio (424B1, 424B2, 424B4 y 424B5), los 8-K con item 1.02, 1.03, 2.04, 3.01, 3.02 y 4.02, y cualquier documento en el que haya aparecido una frase vigilada, que va citada debajo. Lo demás va en tinta normal. Una cita marcada «por primera vez» es una frase que no estaba en el informe previo del mismo tipo de esa empresa. La etiqueta del formulario lleva a su explicación.

Emisiones y dilución

1. ACXPAcurx Pharmaceuticals, Inc.S-3/ACapacidad de emisión registrada (enmienda)EDGAR
   En el documentoContrasplit de accionestexto original ▸

   …000. During the 12 calendar months prior to, and including, the date of this prospectus, we have sold $5.5 million of securities pursuant to General Instruction I.B.6 of Form S-3. On August 4, 2025, we effected a 1-for-20 reverse stock split pursuant to which every 20 shares of our issued and outstanding common stock were reclassified as one share of common stock (the “Reverse Stock Split”). The Reverse Stock Split had no impact on the par…
2. CELUCelularity Inc424B3Prospecto suplementario o de reventaEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …our inception, have no cellular therapeutic candidates approved for commercial sale and we anticipate that we will incur substantial net losses in the future. ● Our historical operating results indicate substantial doubt exists related to our ability to continue as a going concern. ● We will need substantial additional financing to develop our therapeutics and implement our operating plans. If we fail to obtain additional financing, we may be unable to complete the development…
3. FBLGFibroBiologics, Inc.424B3Prospecto suplementario o de reventaEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …Withum Smith+Brown, PC, an independent registered public accounting firm, as stated in their report incorporated by reference herein (which report includes an explanatory paragraph about the existence of substantial doubt concerning the Company’s ability to continue as a going concern). Such audited financial statements are incorporated herein by reference in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. WHERE YOU CAN FIND ADDITIONAL…
4. JBIOJade Biosciences, Inc.424B3Prospecto suplementario o de reventaEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …results of its operations and its cash flows for the period from June 18, 2024 (inception) to December 31, 2024 in conformity with accounting principles generally accepted in the United States of America. Substantial Doubt about the Company’s Ability to Continue as a Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company…

   En el documentoContrasplit de accionestexto original ▸

   …Closing Financing were converted into shares of Common Stock in accordance with the Exchange Ratio (as defined herein). 1 Table of Contents Immediately prior to the consummation of the Merger, Aerovate effected a 1-for-35 reverse stock split of Aerovate common stock (as defined herein), which became legally effective on April 28, 2025 (the “Reverse Stock Split”). Following the Reverse Stock Split, and as a result of and upon the First Effective…
5. MDCXMedicus Pharma Ltd.S-3Capacidad de emisión registradaEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …EisnerAmper LLP, independent registered public accounting firm, as stated in their report which is incorporated by reference herein which report includes an explanatory paragraph about the existence of substantial doubt concerning the Company's ability to continue as a going concern. Such financial statements have been incorporated by reference herein in reliance on the report of such firm given upon their authority as experts in accounting and auditing. The consolidated balance…

   En el documentoPrograma de venta continua de acciones (ATM)texto original ▸

   …soliciting an offer to buy these securities, in any jurisdiction where the offer or sale is not permitted. Subject to completion, dated December 29, 2025 PROSPECTUS Up to $15,349,674 Common Shares We have entered into an At the Market Offering Sales Agreement dated as of December 29, 2025 (the “sales agreement”) with Maxim Group LLC (“Maxim”) and Yorkville Securities, LLC (“Yorkville”) (each of Maxim and Yorkville individually an “Agent” and…
6. MNOVMEDICINOVA INC424B5Nueva emisión de acciones con precioEDGAR
7. PPCBPropanc Biopharma, Inc.S-1Capacidad de emisión registradaEDGAR
   En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸

   …financial statements, the Company has no revenue generating operations and has an accumulated deficit. In addition, the Company has experienced negative cash flows from operations since inception. This raises substantial doubt about its ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement its business plan. There can be no assurance that any additional…
8. APREAprea Therapeutics, Inc.424B3Prospecto suplementario o de reventaEDGAR
9. ARCTArcturus Therapeutics Holdings Inc.S-3Capacidad de emisión registradaEDGAR
10. CMPXCompass Therapeutics, Inc.S-3Capacidad de emisión registradaEDGAR
11. DTILPRECISION BIOSCIENCES INCS-3Capacidad de emisión registradaEDGAR
12. MDCXMedicus Pharma Ltd.424B3Prospecto suplementario o de reventaEDGAR
13. MDCXMedicus Pharma Ltd.424B3Prospecto suplementario o de reventaEDGAR
14. MDCXMedicus Pharma Ltd.424B3Prospecto suplementario o de reventaEDGAR
15. MDCXMedicus Pharma Ltd.424B3Prospecto suplementario o de reventaEDGAR
16. MDCXMedicus Pharma Ltd.424B3Prospecto suplementario o de reventaEDGAR
17. MDCXMedicus Pharma Ltd.424B3Prospecto suplementario o de reventaEDGAR

Participaciones y control

1. GMABGENMAB A/SSC 13D/ACambio en participación significativaEDGAR
2. INDPIndaptus Therapeutics, Inc.SC 13D/ACambio en participación significativaEDGAR
3. INDPIndaptus Therapeutics, Inc.SC 13D/ACambio en participación significativaEDGAR
4. INDVIndivior Pharmaceuticals, Inc.SC 13D/ACambio en participación significativaEDGAR
5. NERVMinerva Neurosciences, Inc.SC 13D/ACambio en participación significativaEDGAR
6. VRCAVerrica Pharmaceuticals Inc.SC 13D/ACambio en participación significativaEDGAR

Informes y hechos relevantes

1. COLLCOLLEGIUM PHARMACEUTICAL, INC8-KFin de acuerdo materialEDGAR
2. CYPHCYPHERPUNK TECHNOLOGIES INC.8-KFin de acuerdo materialEDGAR
3. ADPTAdaptive Biotechnologies Corp8-KOtros hechos relevantesEDGAR
4. BCABBioAtla, Inc.8-KOtros hechos relevantesEDGAR
5. BFRGBullFrog AI Holdings, Inc.8-KOtros hechos relevantesEDGAR
6. CYPHCYPHERPUNK TECHNOLOGIES INC.8-KOtros hechos relevantesEDGAR
7. LITSLite Strategy, Inc.8-KCambio en el consejo o la direcciónEDGAR
8. MDCXMedicus Pharma Ltd.8-KNuevo acuerdo materialEDGAR
9. MNOVMEDICINOVA INC8-KNuevo acuerdo materialEDGAR
10. RAREUltragenyx Pharmaceutical Inc.8-KOtros hechos relevantesEDGAR
11. VRCAVerrica Pharmaceuticals Inc.8-KCambio en el consejo o la direcciónEDGAR

Juntas de accionistas

1. KALAKALA BIO, Inc.DEF 14AConvocatoria de junta de accionistasEDGAR
2. LITSLite Strategy, Inc.DEF 14AConvocatoria de junta de accionistasEDGAR

← lunes 29 de diciembre de 2025 · miércoles 31 de diciembre de 2025 →

Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.